Visit AACR Booth #1553 to explore groundbreaking research featured in the latest issue of Blood Cancer Discovery and learn how the journal supports authors from presubmission to post-publication. #IMS26

Claudio Cerchione, MD, PhD, outlines practice gaps around utilization of upfront quadruplet induction during the Industry Symposium, which also folded in pt perspectives on treatment tolerability and QoL for individualizing therapy. #IMS26

ProMMise platform trial is exploring belantamab dosing guided by patient-reported symptoms, without an ocular assessment. Rakesh Popat, MD, PhD, shared ProMMise data during the first Abstract Session at #IMS26.

Murali Janakiraman, MD, shared data on pts treated sequentially w/ BCMA & GPRC5D therapies & a hepta-exposed subset, in the largest-to-date international cohort in the IMWG Immunotherapy Registry. #IMS26

Niels van de Donk, MD, PhD, spoke abt a mixed cure model to estimate statistical cure fraction - % of pts w/o excess mortality & long-term disease control. In MajesTEC-3, statistical cure fraction w/ Tec-Dara was 86.6% vs 0% w/ DVd or DPd. #IMS26

Read this Blood Cancer Discovery article by #IMS26 speakers Hans Lee and Krina Patel, “CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models.” buff.ly/hlMLTns

At 4:00 PM in Hall 5: How to Treat First Relapse? #IMS26

Read this Blood Cancer Discovery article by #IMS26 speakers Katja Weisel and Marc Raab, “Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Enager Therapy.” buff.ly/xDaup9Q

At the #IMS26 Keynote address, Michael Dustin, PhD, FRS, whose pioneering work illuminated the immunological synapse, spoke on findings on T-cell activation dynamics from fluorescence microscopy-based analyses of supported lipid bilayers.

Roberto Mina, MD, spoke on curative strategies in myeloma during the NDMM session. He summarized the 3 pillars of the proposed IMS-IMWG definition of cure in MM - depth and sustained duration of MRD negativity, and time-limited treatment. #IMS26

Charlotte Pawlyn, MD, PhD, reviews the latest data on maintenance therapy in NDMM, including fixed-duration & dual-agent approaches, & factors to consider for individualizing maintenance treatment. #IMS26

Abstract Sessions begin at 2:30 PM. Join us in Hall 5 for Abstract Session 1 or Lomond Auditorium for Abstract Session 2. #IMS26

A cure for myeloma, defined.

Long considered incurable, myeloma now has a consensus standard: five years off treatment with no detectable disease.

“We are no longer debating whether cure is possible,” said Dr. Nikhil Munshi at #IMS26.

Read more → https://ow.ly/GNG850ZQvKo

At 1:00 PM in Hall 5: Industry Symposium Supported by Sanofi. #IMS26

At 12:00 PM in Alsh: Poster Discussion. #IMS26

Meet the Experts starts at 12:00 PM. #IMS26

Frailty-adapted therapy ➡️ Boisdale
MRD-adapted therapy ➡️ Dochart
Genomics and epigenetics ➡️ Carron

IMS President Philippe Moreau outlined the growth of the IMS and the Annual Meeting, from a 34-person meeting in 1987 to >3800 attendees at #IMS26. “If you want to hear new data in multiple myeloma, this [meeting] is the place to be.”

S Vincent Rajkumar, MD, pays tribute to Robert A. Kyle, MD — myeloma trailblazer who established the IMS & was its first President — celebrating his legacy of integrity, mentorship, and seminal contributions to myeloma. #IMS26

"Welcome to Glasgow... It is a pleasure to bring the [IMS Annual] meeting back to the UK," 39 years after the first IMS meeting.--- Gordon Cook, PhD, DSc. #IMS26

Industry Symposium explores unmet needs in relapsed/refractory multiple myeloma and principles for optimizing selection and sequencing of BCMA-directed therapies, especially in the early relapse setting. #IMS26